Gossamer Bio, Inc.

Businessfiled

Gossamer Bio, Inc. operates in Biotechnology, based in SAN DIEGO. Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sub-sector tags: pharma.

Capital & rounds (filed)filed

Gossamer Bio, Inc. has raised $633M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $230M on 2018-07-20.

Most recent recorded round closed around 2023-07-24.

Valuation (modeled)modeled

Provath models Gossamer Bio, Inc. at approximately $3.2B (range $962M–$4.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.58× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.8× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).

Modeled value ranks above 97% of those peers.

Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.